Skip to Main Content

A Canadian online pharmacy company that figured prominently in a scandal several years ago over a counterfeit cancer medicine sold to U.S. doctors has been fined $34 million, a penalty that a nonprofit advocacy group with ties to the pharmaceutical industry called a “slap on the wrist.”

Companies controlled by Canada Drugs had sold $78 million in mislabeled and unapproved medicines, including two counterfeit batches of the Avastin cancer treatment, that were made in several countries, according to federal prosecutors. The version of Avastin that was sold to U.S. doctors in 2011 did not contain any active ingredient. The brand-name medicine is marketed by Roche.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.